NSCLC
Findings from the phase 3 FLEX study showed that the addition of cetuximab to cisplatin and vinorelbine significantly improved overall survival, compared with cisplatin and vinorelbine alone, in the first-line treatment of EGFR-expressing, advanced non-small-cell lung cancer (NSCLC).
Findings from the phase 3 FLEX study showed that the addition of cetuximab to cisplatin and vinorelbine significantly improved overall survival, compared with cisplatin and vinorelbine alone, in the first-line treatment of <span class="gene" id="21782507-1-223-227">EGFR</span>-expressing, advanced <span class="disease" id="21782507-1-249-275">non-small-cell lung cancer</span> (<span class="disease" id="21782507-1-277-282">NSCLC</span>).